E Fund Management’s Travere Therapeutics TVTX Stock Holding History

E Fund Management’s Portfolio TVTX Stock Details TVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$473K	Sell	8,328 -10,834	-57%	-$480K	0.01%	282
2026 Q1	$569K	Buy	+19,162	New	+$573K	0.02%	266
2025 Q2	$204K	Buy	13,789 +236	+2%	+$3.91K	0.01%	360
2025 Q1	$243K	Buy	13,553 +1,072	+9%	+$21.8K	0.01%	343
2024 Q4	$217K	Buy	+12,481	New	+$221K	0.01%	353
2024 Q3	–	Sell	-11,071	Closed	-$91K	–	369
2024 Q2	$91K	Sell	11,071 -17,057	-61%	-$115K	0.01%	306
2024 Q1	$217K	Buy	28,128 +5,218	+23%	+$44K	0.01%	329
2023 Q4	$206K	Buy	22,910 +4,314	+23%	+$31.4K	0.01%	278
2023 Q3	$166K	Sell	18,596 -8,198	-31%	-$116K	0.01%	268
2023 Q2	$412K	Buy	26,794 +8,262	+45%	+$150K	0.03%	160
2023 Q1	$417K	Buy	18,532 +1,781	+11%	+$37.9K	0.03%	151
2022 Q4	$352K	Buy	16,751 +2,606	+18%	+$55.2K	0.03%	206
2022 Q3	$349K	Sell	14,145 -809	-5%	-$20.9K	0.03%	209
2022 Q2	$362K	Buy	14,954 +7,003	+88%	+$176K	0.03%	204
2022 Q1	$205K	Buy	+7,951	New	+$211K	0.01%	292

Other funds holding TVTX

Jupiter Topco New York $245B AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

NAMI

Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

E Fund Management's TVTX Position: Q2 2026 in Review

E Fund Management reduced its Travere Therapeutics (TVTX) stake by 57% in Q2 2026, selling an estimated $480K and leaving 8,328 shares worth $473K. The position accounts for 0.01% of the portfolio, ranked #282.

E Fund Management first reported a position in TVTX in Q1 2022 and has held it in 15 quarters since. The position peaked at $569K in Q1 2026. 319 funds tracked by Wall St. Rank hold TVTX as of Q2 2026.

E Fund Management held 8,328 shares of Travere Therapeutics worth $473K as of Q2 2026.
E Fund Management sold 10,834 Travere Therapeutics shares in Q2 2026, an estimated $480K.
Travere Therapeutics made up 0.01% of E Fund Management's portfolio in Q2 2026, its #282 holding.
E Fund Management first reported a position in Travere Therapeutics in Q1 2022 and has held it in 15 quarters since.
E Fund Management's Travere Therapeutics position peaked at $569K in Q1 2026.
319 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2026.

Based on E Fund Management's 13F filing for Q2 2026, filed 11 Aug 2026.